Cellply, a Bologna-based deep tech company developing analytical tools for immunotherapy and cell-based therapy development, has secured €7.15 million in funding and opened a round extension.
The round was led by Enea Tech and Biomedical Foundation, with participation from CDP Venture Capital and existing investors. The company develops single-cell analysis technologies for characterizing therapeutic modalities, with its flagship VivaCyte platform combining microfluidics, automated imaging, AI-driven analysis, and software.
Cellply said the new capital will be used to expand the international commercial presence of VivaCyte and to develop automated functional testing solutions for ATMP quality control. The goal is to improve cell potency assessment and help streamline batch release as advanced therapies move toward broader clinical and commercial use.
The funding comes as demand grows for more standardized and scalable quality control tools across the cell therapy and regenerative medicine market.
The round was led by Enea Tech and Biomedical Foundation, with participation from CDP Venture Capital and existing investors. The company develops single-cell analysis technologies for characterizing therapeutic modalities, with its flagship VivaCyte platform combining microfluidics, automated imaging, AI-driven analysis, and software.
Cellply said the new capital will be used to expand the international commercial presence of VivaCyte and to develop automated functional testing solutions for ATMP quality control. The goal is to improve cell potency assessment and help streamline batch release as advanced therapies move toward broader clinical and commercial use.
The funding comes as demand grows for more standardized and scalable quality control tools across the cell therapy and regenerative medicine market.